The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Monoclonal antibodies specific for simian virus 40 tumor antigens
Harlow, E., Crawford, L. V., Pim, D. C., & Williamson, N. M. (1981) · Journal of Virology · doi:10.1128/jvi.39.3.861-869.1981 · Cited by 1,039
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
Self-citationMichalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Mapping of the p53 and mdm-2 interaction domains.
Chen, J., Marechal, V, & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 653
Cited by
Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., et al. (2000) · Accounts of Chemical Research · doi:10.1021/ar000033j · Cited by 4,978
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Massova, I., & Kollman, P. A. (2000) · Perspectives in Drug Discovery and Design · doi:10.1023/a:1008763014207 · Cited by 1,015
A simple physical model for binding energy hot spots in protein–protein complexes
Kortemme, T., & Baker, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485799 · Cited by 804
Massova, I., & Kollman, P. A. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990935j · Cited by 780
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
Self-citationOPTIMIZING LONG INTRINSIC DISORDER PREDICTORS WITH PROTEIN EVOLUTIONARY INFORMATION
PENG, K., VUCETIC, S., RADIVOJAC, P., BROWN, C. J., DUNKER, A. K., & OBRADOVIC, Z. (2005) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720005000886 · Cited by 496
Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., & Shkedy, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14973 · Cited by 461
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363
Self-citationHelical β-Peptide Inhibitors of the p53-hDM2 Interaction
Kritzer, J. A., Lear, J. D., Hodsdon, M. E., & Schepartz, A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031625a · Cited by 314
Computational alanine scanning of the 1:1 human growth hormone–receptor complex
Huo, S., Massova, I., & Kollman, P. A. (2002) · Journal of Computational Chemistry · doi:10.1002/jcc.1153 · Cited by 305
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Comparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189
Self-citationA Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
Disruption of protein–protein interactions: Towards new targets for chemotherapy
Loregian, A., & Palù, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20356 · Cited by 108
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
Wang, H., Yu, D., Agrawal, S., & Zhang, R. (2003) · The Prostate · doi:10.1002/pros.10187 · Cited by 78
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
DEGRONOPEDIA: a web server for proteome-wide inspection of degrons
Szulc, N. A., Stefaniak, F., Piechota, M., Soszyńska, A., Piórkowska, G., Cappannini, A., Bujnicki, J. M., Maniaci, C., & Pokrzywa, W. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae238 · Cited by 35
Metadata
- Authors
- Böttger, A., Böttger, V., Garcia-Echeverria, C., Chène, P., Hochkeppel, H.-K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., & Lane, D. P.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 1997-07
- Volume
- 269
- Issue
- 5
- Pages
- 744-756
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W2084374650
- Cited by
- 252
- References
- 25
- Type
- book review
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.